Citi upgrades The Medicines Company (Nasdaq: MDCO) from Hold to Buy. Price target increased from $23 to $29.

This article: 154 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE